UBS initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $12 price target As one of the more potent anti-fibrotics UBS has ...

s potential in the market. A key element is the company’s promising drug, denifanstat, a fatty acid synthase inhibitor, which has shown strong efficacy in Phase 2b trials, particularly among more ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, (GLOBE ...

STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types Gene expres ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress ... Cancers Symposium® will focus on treatment strategies in early-stage lung cancers, ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

Patients with sarcoidosis treated with ACE inhibitors had greater mortality risk than those treated with angiotensin receptor blockers.

DOYLESTOWN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through ...

Androgenetic alopecia (AGA) is the leading cause of hair loss in both men and women. Experts outline current and emerging ...